Boothbay Fund Management
ATRA icon

Boothbay Fund Management’s Atara Biotherapeutics ATRA Stock Holding History

Boothbay Fund Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6
Closed -$591K – 659
2018
Q3 		$591K Hold
6
– – 0.06% 313
2018
Q2 		$526K Buy
+6
New +$6.45K 0.05% 337

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Boothbay Fund Management's ATRA Position: Q4 2020 in Review

Boothbay Fund Management sold out of Atara Biotherapeutics (ATRA) in Q4 2020, closing a stake of 1,954 shares — an estimated $633K sold.

Boothbay Fund Management first reported a position in ATRA in Q3 2020 and held it in 1 quarter. The position peaked at $633K in Q3 2020. 148 funds tracked by Wall St. Rank hold ATRA as of Q4 2020.

  • Boothbay Fund Management reported no remaining Atara Biotherapeutics position as of Q4 2020 after selling out during the quarter.
  • Boothbay Fund Management sold 1,954 Atara Biotherapeutics shares in Q4 2020, an estimated $633K.
  • Boothbay Fund Management first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 1 quarter.
  • Boothbay Fund Management's Atara Biotherapeutics position peaked at $633K in Q3 2020.
  • 148 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2020.

Based on Boothbay Fund Management's 13F filing for Q4 2020, filed 12 Feb 2021.